Is Hoth Therapeutics, Inc. (HOTH) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 45.7% / 30% | 0.3% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.2% / 33% | 45.7% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.4% / 33% | 91.3% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 45.7% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.4% / 33% | 91.3% / 33% | 0.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -151.1% | |
| Return on Assets (ROA) | -84.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Total Debt | $31,075 |
| Debt-to-Equity | 0.2 |
| Current Ratio | 8.8 |
| Total Assets | $8M |
Price & Trading
| Last Close | $0.84 |
| 50-Day MA | $0.98 |
| 200-Day MA | $1.23 |
| Avg Volume | 536K |
| Beta | 0.5 |
|
52-Week Range
$0.66
| |
About Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Hoth Therapeutics, Inc. (HOTH) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Hoth Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Hoth Therapeutics, Inc.'s debt ratio?
Hoth Therapeutics, Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.
What are Hoth Therapeutics, Inc.'s key financial metrics?
Hoth Therapeutics, Inc. has a market capitalization of $12M. Return on equity stands at -151.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.